Cargando…

Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

Detalles Bibliográficos
Autores principales:	Bakker, Daphne S., ter Linde, José J. M., Amini, Mojtaba M., Ariëns, Lieneke F. M., van Luijk, Chantal M., de Bruin‐Weller, Marjolein S., Thijs, Judith L., Vercoulen, Yvonne, van Wijk, Femke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292644/ https://www.ncbi.nlm.nih.gov/pubmed/34449906 http://dx.doi.org/10.1111/all.15064

Ejemplares similares

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis
por: Bakker, D.S., et al.
Publicado: (2019)

Dupilumab facial redness: Positive effect of itraconazole
por: de Beer, Fleur S.A., et al.
Publicado: (2019)

EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
por: Bakker, Daphne S., et al.
Publicado: (2020)

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
por: ARIËNS, Lieneke F. M., et al.
Publicado: (2021)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023)

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
por: Spekhorst, Lotte S., et al.
Publicado: (2020)

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry
por: Kamphuis, Esmé, et al.
Publicado: (2022)

Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
por: ACHTEN, Roselie E., et al.
Publicado: (2022)

Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: BOESJES, Celeste M., et al.
Publicado: (2023)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis
por: Spekhorst, Lotte S., et al.
Publicado: (2023)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology
por: Ariens, Lieneke FM, et al.
Publicado: (2017)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Immune monitoring and treatment in immune-mediated inflammatory diseases
por: van Wijk, Femke, et al.
Publicado: (2022)

Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis
por: van Eijs, Mick J.M., et al.
Publicado: (2023)

The long‐term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis—52 week results from the Dutch BioDay Registry
por: Voorberg, Angelique N., et al.
Publicado: (2022)

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment
por: Bakker, Daphne S., et al.
Publicado: (2019)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

Effects of dupilumab treatment on patch test reactions: A retrospective evaluation
por: de Wijs, Linde E. M., et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Conjunctival microcirculation in patients with traumatic brain injury
por: Klijn, E, et al.
Publicado: (2008)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

Dupilumab-Induced Pancreatitis
por: Jasti, Vivek V., et al.
Publicado: (2023)

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2020)

Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
por: Thyssen, J.P., et al.
Publicado: (2019)

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
por: Griffiths, Christopher, et al.
Publicado: (2021)

New Developments in Biomarkers for Atopic Dermatitis
por: Thijs, Judith L., et al.
Publicado: (2015)

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2022)

Successful treatment of trichothiodystrophy with dupilumab
por: Gruber, R., et al.
Publicado: (2021)

Conjunctival myxoma masquerading as conjunctival lymphoma: A case report
por: Alkharashi, Majed, et al.
Publicado: (2022)

The Combination of Dupilumab with Other Monoclonal Antibodies
por: Gisondi, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3sde2ah4tkscc5aduhr7v4dspr